Annual CFF
$26.71 M
-$46.16 M-63.35%
31 December 2023
Summary:
Aclaris Therapeutics annual cash flow from financing activities is currently $26.71 million, with the most recent change of -$46.16 million (-63.35%) on 31 December 2023. During the last 3 years, it has risen by +$8.33 million (+45.36%). ACRS annual CFF is now -88.13% below its all-time high of $225.05 million, reached on 31 December 2021.ACRS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$22.00 K
+$33.00 K+300.00%
30 September 2024
Summary:
Aclaris Therapeutics quarterly cash flow from financing activities is currently $22.00 thousand, with the most recent change of +$33.00 thousand (+300.00%) on 30 September 2024. Over the past year, it has increased by +$109.00 thousand (+125.29%). ACRS quarterly CFF is now -99.98% below its all-time high of $135.87 million, reached on 30 June 2021.ACRS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$5000.00
+$109.00 K+104.81%
30 September 2024
Summary:
Aclaris Therapeutics TTM cash flow from financing activities is currently $5000.00, with the most recent change of +$109.00 thousand (+104.81%) on 30 September 2024. Over the past year, it has dropped by -$26.69 million (-99.98%). ACRS TTM CFF is now -100.00% below its all-time high of $244.17 million, reached on 30 June 2021.ACRS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -63.4% | +125.3% | -100.0% |
| 3 y3 years | +45.4% | +100.2% | -100.0% |
| 5 y5 years | -79.2% | +131.4% | -100.0% |
ACRS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -88.1% | +45.4% | -100.0% | +100.2% | -100.0% | +104.8% |
| 5 y | 5 years | -88.1% | +188.1% | -100.0% | +100.1% | -100.0% | +100.0% |
| alltime | all time | -88.1% | +188.1% | -100.0% | +100.1% | -100.0% | +100.0% |
Aclaris Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $22.00 K(-300.0%) | $5000.00(-104.8%) |
| June 2024 | - | -$11.00 K(-80.0%) | -$104.00 K(-100.4%) |
| Mar 2024 | - | -$55.00 K(-212.2%) | $26.65 M(-0.2%) |
| Dec 2023 | $26.71 M(-63.3%) | $49.00 K(-156.3%) | $26.71 M(+0.0%) |
| Sept 2023 | - | -$87.00 K(-100.3%) | $26.69 M(-0.3%) |
| June 2023 | - | $26.74 M(>+9900.0%) | $26.77 M(-63.2%) |
| Mar 2023 | - | $0.00(-100.0%) | $72.84 M(-0.0%) |
| Dec 2022 | $72.87 M(-67.6%) | $37.00 K(-436.4%) | $72.87 M(+0.1%) |
| Sept 2022 | - | -$11.00 K(-100.0%) | $72.83 M(+18.9%) |
| June 2022 | - | $72.81 M(>+9900.0%) | $61.27 M(-50.7%) |
| Mar 2022 | - | $30.00 K(-1600.0%) | $124.33 M(-44.8%) |
| Dec 2021 | $225.05 M(+1125.0%) | -$2000.00(-100.0%) | $225.05 M(-3.4%) |
| Sept 2021 | - | -$11.57 M(-108.5%) | $232.88 M(-4.6%) |
| June 2021 | - | $135.87 M(+34.9%) | $244.17 M(+125.7%) |
| Mar 2021 | - | $100.75 M(+1186.9%) | $108.20 M(+489.0%) |
| Dec 2020 | $18.37 M(-160.6%) | $7.83 M(-2916.2%) | $18.37 M(-194.4%) |
| Sept 2020 | - | -$278.00 K(+186.6%) | -$19.47 M(+1.1%) |
| June 2020 | - | -$97.00 K(-100.9%) | -$19.26 M(-0.1%) |
| Mar 2020 | - | $10.92 M(-136.4%) | -$19.28 M(-36.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$30.32 M(-123.6%) | -$30.01 M(>+9900.0%) | -$30.32 M(-123.7%) |
| Sept 2019 | - | -$70.00 K(-40.2%) | $127.88 M(-0.1%) |
| June 2019 | - | -$117.00 K(-2.5%) | $127.97 M(+0.1%) |
| Mar 2019 | - | -$120.00 K(-100.1%) | $127.78 M(-0.4%) |
| Dec 2018 | $128.26 M(+27.8%) | $128.18 M(>+9900.0%) | $128.26 M(>+9900.0%) |
| Sept 2018 | - | $19.00 K(-106.4%) | $0.00(-100.0%) |
| June 2018 | - | -$299.00 K(-183.5%) | $80.90 M(-19.5%) |
| Mar 2018 | - | $358.00 K(-559.0%) | $100.53 M(+0.1%) |
| Dec 2017 | $100.39 M(-14.1%) | -$78.00 K(-100.1%) | $100.39 M(-49.5%) |
| Sept 2017 | - | $80.92 M(+318.5%) | $198.73 M(+68.7%) |
| June 2017 | - | $19.34 M(+9152.2%) | $117.82 M(+0.7%) |
| Mar 2017 | - | $209.00 K(-99.8%) | $117.03 M(+0.2%) |
| Dec 2016 | $116.83 M(+21.2%) | $98.27 M(>+9900.0%) | $116.83 M(+52.5%) |
| Sept 2016 | - | $13.00 K(-99.9%) | $76.62 M(-33.9%) |
| June 2016 | - | $18.55 M(-68.1%) | $115.86 M(+20.2%) |
| Dec 2015 | $96.41 M(+810.9%) | $58.06 M(+47.9%) | $96.41 M(+151.4%) |
| Sept 2015 | - | $39.25 M(-6011.4%) | $38.36 M(-4385.7%) |
| June 2015 | - | -$664.00 K(+187.4%) | -$895.00 K(+287.4%) |
| Mar 2015 | - | -$231.00 K | -$231.00 K |
| Dec 2014 | $10.58 M | - | - |
FAQ
- What is Aclaris Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aclaris Therapeutics?
- What is Aclaris Therapeutics annual CFF year-on-year change?
- What is Aclaris Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aclaris Therapeutics?
- What is Aclaris Therapeutics quarterly CFF year-on-year change?
- What is Aclaris Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aclaris Therapeutics?
- What is Aclaris Therapeutics TTM CFF year-on-year change?
What is Aclaris Therapeutics annual cash flow from financing activities?
The current annual CFF of ACRS is $26.71 M
What is the all time high annual CFF for Aclaris Therapeutics?
Aclaris Therapeutics all-time high annual cash flow from financing activities is $225.05 M
What is Aclaris Therapeutics annual CFF year-on-year change?
Over the past year, ACRS annual cash flow from financing activities has changed by -$46.16 M (-63.35%)
What is Aclaris Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ACRS is $22.00 K
What is the all time high quarterly CFF for Aclaris Therapeutics?
Aclaris Therapeutics all-time high quarterly cash flow from financing activities is $135.87 M
What is Aclaris Therapeutics quarterly CFF year-on-year change?
Over the past year, ACRS quarterly cash flow from financing activities has changed by +$109.00 K (+125.29%)
What is Aclaris Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ACRS is $5000.00
What is the all time high TTM CFF for Aclaris Therapeutics?
Aclaris Therapeutics all-time high TTM cash flow from financing activities is $244.17 M
What is Aclaris Therapeutics TTM CFF year-on-year change?
Over the past year, ACRS TTM cash flow from financing activities has changed by -$26.69 M (-99.98%)